Clinical Trials Browser

Interventional × margetuximab × Breast × Clear all

NCT04425018 2025-11-18

MARGOT

Phase 2 Active not recruiting

174 enrolled 19 charts

Breast Neoplasms

NCT01828021 2025-03-13

Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer

Phase 2 Completed

25 enrolled 8 charts

Breast Neoplasms, Recurrence

NCT01148849 2025-02-26

Safety Study of MGAH22 in HER2-positive Carcinomas

Phase 1 Completed

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT03219268 2023-12-21

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Phase 1 Completed

BreastGastrointestinalGynecologicHead & NeckOther hematologic neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Cholangiocarcinoma, Hematologic Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04262804 2023-08-22

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Phase 2 Unknown

Breast Cancer Metastatic

NCT05227131 2022-07-11

MARGARET

Phase 2 Withdrawn

Breast Neoplasms